SG10201913266UA - Materials and methods for delivering nucleic acids to cochlear and vestibular cells - Google Patents
Materials and methods for delivering nucleic acids to cochlear and vestibular cellsInfo
- Publication number
- SG10201913266UA SG10201913266UA SG10201913266UA SG10201913266UA SG10201913266UA SG 10201913266U A SG10201913266U A SG 10201913266UA SG 10201913266U A SG10201913266U A SG 10201913266UA SG 10201913266U A SG10201913266U A SG 10201913266UA SG 10201913266U A SG10201913266U A SG 10201913266UA
- Authority
- SG
- Singapore
- Prior art keywords
- cochlear
- materials
- methods
- nucleic acids
- delivering nucleic
- Prior art date
Links
- 239000000463 material Substances 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 230000001720 vestibular Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Radiology & Medical Imaging (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562266462P | 2015-12-11 | 2015-12-11 | |
| US201562266477P | 2015-12-11 | 2015-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201913266UA true SG10201913266UA (en) | 2020-02-27 |
Family
ID=59013436
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804814YA SG11201804814YA (en) | 2015-12-11 | 2016-12-12 | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
| SG10201913266UA SG10201913266UA (en) | 2015-12-11 | 2016-12-12 | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804814YA SG11201804814YA (en) | 2015-12-11 | 2016-12-12 | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11167042B2 (en) |
| EP (2) | EP3984550A1 (en) |
| JP (3) | JP6990182B2 (en) |
| KR (1) | KR20180097631A (en) |
| CN (2) | CN109310745B (en) |
| AU (1) | AU2016366846B2 (en) |
| CA (1) | CA3007476A1 (en) |
| ES (1) | ES2903000T3 (en) |
| SG (2) | SG11201804814YA (en) |
| WO (1) | WO2017100791A1 (en) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11026418B2 (en) * | 2014-11-26 | 2021-06-08 | Microban Products Company | Surface disinfectant with residual biocidal property |
| EP3984550A1 (en) | 2015-12-11 | 2022-04-20 | Massachusetts Eye & Ear Infirmary | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
| CN110225975A (en) | 2016-08-23 | 2019-09-10 | 阿库斯股份有限公司 | For treating the composition and method of non-age-dependent hearing impairment in people experimenter |
| US11730827B2 (en) | 2017-02-06 | 2023-08-22 | Children's Medical Center Corporation | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
| EP3595634B1 (en) * | 2017-03-17 | 2024-03-27 | Rescue Hearing Inc | Gene therapy constructs and methods for treatment of hearing loss |
| WO2019005853A2 (en) * | 2017-06-26 | 2019-01-03 | Arizona Board Of Regents On Behalf Of Arizona State University | Crispr-based synthetic gene circuits as next generation gene therapy of inner ear |
| WO2019028246A2 (en) * | 2017-08-03 | 2019-02-07 | University Of Iowa Research Foundation | Methods of treating genetic hearing loss |
| CN111936171A (en) | 2017-12-19 | 2020-11-13 | 阿库斯股份有限公司 | AAV-mediated delivery of therapeutic antibodies to the inner ear |
| DE102018100619A1 (en) | 2018-01-12 | 2019-07-18 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Gentherapeutic treatment of deafness |
| US11905522B2 (en) | 2018-01-16 | 2024-02-20 | Cls Therapeutics Limited | Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity |
| DE102018103924A1 (en) | 2018-02-21 | 2019-08-22 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Gentherapeutic treatment of deafness |
| EP3762040A4 (en) * | 2018-03-05 | 2022-01-05 | Children's Medical Center Corporation | Compositions and methods for delivering nucleic acids to cochlear and vestibular cells |
| WO2019183641A1 (en) | 2018-03-23 | 2019-09-26 | Massachusetts Eye And Ear Infirmary | Crispr/cas9-mediated exon-skipping approach for ush2a-associated usher syndrome |
| WO2019200016A1 (en) * | 2018-04-10 | 2019-10-17 | President And Fellows Of Harvard College | Aav vectors encoding clarin-1 or gjb2 and uses thereof |
| US11660353B2 (en) | 2018-04-27 | 2023-05-30 | Decibel Therapeutics, Inc. | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems |
| CA3098198A1 (en) * | 2018-04-27 | 2019-10-31 | Decibel Therapeutics, Inc. | Myosin 15 promoters and uses thereof |
| BR112020022858A2 (en) | 2018-05-11 | 2021-02-23 | Massachusetts Eye And Ear Infirmary | hepatic specific tropism of adeno-associated virus |
| BR112020026606A2 (en) * | 2018-06-25 | 2021-04-06 | Akouos, Inc. | METHODS OF TREATMENT OF HEARING LOSS AND/OR LOSS OF VISION ASSOCIATED WITH CLRN1 |
| US20210330814A1 (en) * | 2018-07-13 | 2021-10-28 | Akouos, Inc. | Methods of treating non-syndromic sensorineural hearing loss |
| EP3829652A4 (en) * | 2018-08-01 | 2022-05-11 | University of Maryland, Baltimore | Modulation of mtorc1 activity and autophagy via cib2-rheb interaction |
| EP3856227A4 (en) | 2018-09-27 | 2022-07-06 | Akouos, Inc. | A method for treating an auditory neuropathy spectrum disorder |
| AU2019357048A1 (en) * | 2018-10-11 | 2021-05-27 | Decibel Therapeutics, Inc. | AAV1 vectors and uses thereof for treatment of otic indications |
| WO2020097369A1 (en) * | 2018-11-07 | 2020-05-14 | Akouos, Inc. | Compositions and methods of inducing differentiation of a hair cell |
| US20230056182A1 (en) * | 2018-11-07 | 2023-02-23 | Akouos, Inc. | Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear |
| HUE063458T2 (en) * | 2019-01-18 | 2024-01-28 | Pasteur Institut | Aav-mediated gene therapy restoring the otoferlin gene |
| EP3921032A4 (en) * | 2019-02-08 | 2022-11-30 | Decibel Therapeutics, Inc. | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems |
| CA3129422A1 (en) | 2019-02-08 | 2020-08-13 | Decibel Therapeutics, Inc. | Myosin 15 promoters and uses thereof |
| EP3953461A4 (en) * | 2019-04-09 | 2023-05-31 | The Regents of The University of California | Long-lasting analgesia via targeted in vivo epigenetic repression |
| CN110129368B (en) * | 2019-04-22 | 2021-03-09 | 中国科学院脑科学与智能技术卓越创新中心 | AAV vector for infecting support cell and hair cell |
| US11278013B2 (en) | 2019-04-26 | 2022-03-22 | Usher 2020 Foundation | Large animal model for developing therapeutic agents to treat impaired ophthalmic function in usher syndrome |
| US20220233715A1 (en) * | 2019-05-08 | 2022-07-28 | Center For Excellence In Brain Science And Intelligence Technology, Chinese Academy Of Sciences | Aav mutant that efficiently infects supporting cells |
| CN110423778B (en) * | 2019-07-26 | 2023-04-21 | 上海科技大学 | Application of retrograde recombinant type 2 adeno-associated virus in infection of spiral neurons |
| WO2021067448A1 (en) * | 2019-09-30 | 2021-04-08 | Applied Genetic Technologies Corporation | Adeno-associated virus (aav) systems for treatment of genetic hearing loss |
| EP4051698A4 (en) * | 2019-10-30 | 2024-03-27 | Decibel Therapeutics, Inc. | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems |
| JP2023500670A (en) * | 2019-11-04 | 2023-01-10 | デシベル セラピューティクス インコーポレイテッド | Cochlear inner ear hair cell promoter and uses thereof |
| WO2021108512A1 (en) * | 2019-11-27 | 2021-06-03 | Icahn School Of Medicine At Mount Sinai | Gene therapy for the regeneration of auditory hair cells |
| IL295747A (en) | 2020-02-21 | 2022-10-01 | Akouos Inc | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
| CN116096900A (en) * | 2020-05-13 | 2023-05-09 | 阿库斯股份有限公司 | Compositions and methods for treating GJB 2-related hearing loss |
| KR102326582B1 (en) * | 2020-05-15 | 2021-11-16 | 사회복지법인 삼성생명공익재단 | Marker for diagnosing hearing impairment and deafness and use thereof |
| WO2022032151A1 (en) * | 2020-08-07 | 2022-02-10 | University Of Miami | Treatment of sensorineural deafness |
| EP4262882A1 (en) * | 2020-12-18 | 2023-10-25 | Institut Pasteur | Gene therapy for treating usher syndrome |
| CN113604469B (en) * | 2021-08-11 | 2023-01-24 | 复旦大学附属眼耳鼻喉科医院 | CRISPR/CasRx based gene editing method and application thereof |
| WO2023122720A1 (en) * | 2021-12-23 | 2023-06-29 | University Of Rochester | Compositions and methods for delivery of agents to inner ear |
| WO2023147383A1 (en) | 2022-01-25 | 2023-08-03 | Bridgebio Services Inc. | Gene therapy for genetic hearing loss |
| GB202214972D0 (en) * | 2022-10-11 | 2022-11-23 | Ucl Business Ltd | Products and methods for use in treating NDP-related diseases |
| WO2024151703A2 (en) * | 2023-01-12 | 2024-07-18 | Ohio State Innovation Foundation | Gene therapy for treating hearing loss disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5037384B2 (en) | 1988-01-12 | 1995-12-26 | Cornell Res Foundation Inc | Method and apparatus for the treatment of complicated retinal detachments |
| US20040115621A1 (en) | 2000-02-18 | 2004-06-17 | Allen Rodrigo | Ancestral viruses and vaccines |
| US6692526B1 (en) | 2000-03-15 | 2004-02-17 | Michael E. Snyder | Ophthalmological surgery colorant and delivery system |
| CA3072423A1 (en) | 2003-09-30 | 2005-04-14 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| EP1755400A2 (en) | 2004-06-18 | 2007-02-28 | The University Of Montana | Aav mediated gene delivery to cochlear cells |
| ES2580044T3 (en) | 2005-04-07 | 2016-08-18 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an AAV vector |
| US8388668B2 (en) | 2005-08-05 | 2013-03-05 | Gholam A. Peyman | Methods to regulate polarization of excitable cells |
| WO2011075838A1 (en) * | 2009-12-21 | 2011-06-30 | Audigen Inc. | Method of treating or preventing hearing loss |
| US20150079110A1 (en) | 2012-03-05 | 2015-03-19 | Wake Forest University Health Sciences | Regeneration of inner ear cells |
| CA3182790A1 (en) | 2013-10-11 | 2015-04-16 | Massachusetts Eye & Ear Infirmary | Ancestral adeno-associated virus sequences and uses thereof |
| SG10201804976YA (en) | 2013-12-12 | 2018-07-30 | Broad Inst Inc | Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Genome Editing |
| US10751385B2 (en) * | 2015-02-20 | 2020-08-25 | Institut Pasteur | Prevention and/or treatment of hearing loss or impairment |
| EP3984550A1 (en) | 2015-12-11 | 2022-04-20 | Massachusetts Eye & Ear Infirmary | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
| CN110225975A (en) * | 2016-08-23 | 2019-09-10 | 阿库斯股份有限公司 | For treating the composition and method of non-age-dependent hearing impairment in people experimenter |
-
2016
- 2016-12-12 EP EP21202250.3A patent/EP3984550A1/en active Pending
- 2016-12-12 CN CN201680079432.3A patent/CN109310745B/en active Active
- 2016-12-12 CA CA3007476A patent/CA3007476A1/en active Pending
- 2016-12-12 SG SG11201804814YA patent/SG11201804814YA/en unknown
- 2016-12-12 EP EP16874069.4A patent/EP3386537B1/en active Active
- 2016-12-12 SG SG10201913266UA patent/SG10201913266UA/en unknown
- 2016-12-12 US US16/060,841 patent/US11167042B2/en active Active
- 2016-12-12 AU AU2016366846A patent/AU2016366846B2/en active Active
- 2016-12-12 ES ES16874069T patent/ES2903000T3/en active Active
- 2016-12-12 KR KR1020187019786A patent/KR20180097631A/en not_active Application Discontinuation
- 2016-12-12 JP JP2018529927A patent/JP6990182B2/en active Active
- 2016-12-12 CN CN202211693839.9A patent/CN116236591A/en active Pending
- 2016-12-12 WO PCT/US2016/066225 patent/WO2017100791A1/en active Application Filing
-
2021
- 2021-10-05 US US17/450,008 patent/US12102692B2/en active Active
- 2021-12-03 JP JP2021196596A patent/JP7309827B2/en active Active
-
2023
- 2023-07-05 JP JP2023110371A patent/JP2023145460A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3386537A1 (en) | 2018-10-17 |
| US11167042B2 (en) | 2021-11-09 |
| JP2022046484A (en) | 2022-03-23 |
| AU2016366846B2 (en) | 2022-03-17 |
| EP3386537A4 (en) | 2019-05-15 |
| WO2017100791A1 (en) | 2017-06-15 |
| EP3386537B1 (en) | 2021-10-20 |
| US20180369414A1 (en) | 2018-12-27 |
| CA3007476A1 (en) | 2017-06-15 |
| CN109310745A (en) | 2019-02-05 |
| US12102692B2 (en) | 2024-10-01 |
| JP6990182B2 (en) | 2022-02-15 |
| CN116236591A (en) | 2023-06-09 |
| JP2023145460A (en) | 2023-10-11 |
| EP3984550A1 (en) | 2022-04-20 |
| ES2903000T3 (en) | 2022-03-30 |
| AU2016366846A1 (en) | 2018-06-21 |
| JP2018536420A (en) | 2018-12-13 |
| US20220016262A1 (en) | 2022-01-20 |
| SG11201804814YA (en) | 2018-07-30 |
| JP7309827B2 (en) | 2023-07-18 |
| KR20180097631A (en) | 2018-08-31 |
| CN109310745B (en) | 2022-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201913266UA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| EP3576696A4 (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| IL259321A (en) | Compositions and methods for enhanced gene expression in cone cells | |
| HK1250330A1 (en) | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination | |
| EP3230445C0 (en) | Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides | |
| HK1219503A1 (en) | Methods and compositions for nucleic acid sequencing | |
| HK1218768A1 (en) | Methods for amplification and sequencing using thermostable tthprimpol tthprimpol | |
| SG11201605906UA (en) | Muscle-specific nucleic acid regulatory elements and methods and use thereof | |
| IL243672B (en) | Ligase-assisted nucleic acid circularization and amplification | |
| SG11201606934SA (en) | Improved reprogramming methods and cell culture platforms | |
| SG11201609916RA (en) | Culture method and cell mass | |
| SG11201705853VA (en) | Cell culture device and cell culture method | |
| HUE050306T2 (en) | Oral rehydration composition and methods thereof | |
| HK1249662A1 (en) | Battery electrode and method | |
| GB201410270D0 (en) | Cell delivery system and method | |
| HK1257519A1 (en) | Methods and materials for galgt2 gene therapy | |
| IL246525A0 (en) | Pomegranate derived cell culture and methods for preparing and using the same | |
| SG11201702897WA (en) | Cell culture bag and cell culture method | |
| EP3126500A4 (en) | Dna aptamers specific to cd200r1 and their therapeutic uses | |
| EP3258978A4 (en) | Methods and products for delivering cells | |
| TWI563085B (en) | Dendritic cell tumor vaccine and preparation method thereof | |
| EP3241848A4 (en) | Construction method for recombinant vaccine having anti-cervical cancer cell activity and application thereof | |
| AU2015900510A0 (en) | Methods and products for delivering cells | |
| SG11201709352RA (en) | Method for producing frozen mesenchymal cells and method for producing implantable therapeutic member | |
| GB201509395D0 (en) | Improvements in and relating to nucleic acid probes |